Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in CRSP — CRISPR Therapeutics AG

CIK 1423053 MIAMI, FL
Back to CRSP Full portfolio

Position in CRSP

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$25,404,513
+$841,650 QoQ
Shares Held
465,796
-9.8% QoQ
Ownership
0.482%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#26
of 521 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in CRSP Over Time

Shares Held

Position Value (USD)

Derivatives in CRSP

reported options exposure · as of Jun 30, 2026
CallValue
$13,973,148
CallShares
256,200
PutValue
$15,822,054
PutShares
290,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,088,670,159 across 436 Biotechnology names. CRSP ranks #50 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ONC
BeOne Medicines Ltd.
 1,425,517 $406,229,578
2 BBIO
BridgeBio Pharma, Inc.
 3,760,028 $280,046,885
3 INSM
INSMED Inc
 2,556,973 $272,624,460
4 MDGL
Madrigal Pharmaceuticals, Inc.
 507,233 $272,358,759
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 510,430 $253,545,893
6 JAZZ
Jazz Pharmaceuticals plc
 1,006,676 $242,578,715
7 MANE
Veradermics, Inc
 1,877,775 $230,853,658
8 ROIV
Roivant Sciences Ltd.
 5,576,261 $197,343,876

All Filings in CRSP

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $15,822,054 290,100
2026-06-30 $25,404,513 465,796
2026-06-30 $13,973,148 256,200
2026-03-31 $12,315,873 258,900
2026-03-31 $24,562,863 516,352
2026-03-31 $27,224,311 572,300
2025-12-31 $14,037,401 267,685
2025-12-31 $30,347,028 578,700
2025-12-31 $39,760,008 758,200
2025-09-30 $10,829,815 167,101
2025-09-30 $57,551,280 888,000
2025-09-30 $55,153,310 851,000
2025-06-30 $14,270,976 293,400
2025-06-30 $918,225 18,878
2025-06-30 $47,462,912 975,800
2025-03-31 $14,044,181 412,700
2025-03-31 $8,764,324 257,547
2025-03-31 $14,479,765 425,500
2024-12-31 $31,240,032 793,700
2024-12-31 $11,504,928 292,300
2024-12-31 $34,593,346 878,896
2024-09-30 $32,669,892 695,400
2024-09-30 $13,154,400 280,000
2024-09-30 $24,361,338 518,547
2024-06-30 $38,390,308 710,800
2024-06-30 $20,037,710 371,000
2024-06-30 $7,699,773 142,562
2024-03-31 $56,920,416 835,100
2024-03-31 $16,160,735 237,100
2024-03-31 $33,084,864 485,400
2023-12-31 $43,801,220 699,700
2023-12-31 $72,021,300 1,150,500
2023-12-31 $17,112,273 273,359
2023-09-30 $17,752,029 391,100
2023-09-30 $978,381 21,555
2023-09-30 $17,724,795 390,500
2023-06-30 $22,888,278 407,700
2023-06-30 $4,938,355 87,965
2023-06-30 $19,087,600 340,000
2023-03-31 $8,403,734 185,800
2023-03-31 $11,809,553 261,100
2023-03-31 $7,885,352 174,339
2022-12-31 $16,776,255 412,700
2022-12-31 $6,907,004 169,914
2022-12-31 $18,979,485 466,900
2022-09-30 $14,886,730 227,800
2022-09-30 $365,306 5,590
2022-09-30 $58,174,570 890,200
2022-06-30 $53,374,291 878,300
2022-06-30 $498,800 8,208

Report a Problem

Category
Description
Email (optional, for follow-up)